Announcements

    Drinks

      Scope has updated its analytical report on Sanofi S.A.
      WEDNESDAY, 18/12/2024 - Scope Ratings GmbH
      Download PDF

      Scope has updated its analytical report on Sanofi S.A.

      Following the recent affirmation of the AA/Stable issuer rating, Scope has updated its analytical report on Sanofi S.A.

      This monitoring note does not constitute a credit rating action, nor does it indicate the likelihood that Scope will conduct a credit rating action in the short term. On 6 December 2024, Scope affirmed the AA/Stable issuer rating on Sanofi S.A.. Scope also affirmed the rating for the company’s senior unsecured debt at AA and short-term debt at S-1+.

      The latest information on the credit ratings in this monitoring note along with the associated rating history can be found on www.scoperatings.com.

      Click here to access the full report.

      Related news

      Show all
      Scope affirms BBB-/Stable issuer rating of Germany’s investment holding Haniel

      17/4/2025 Rating announcement

      Scope affirms BBB-/Stable issuer rating of Germany’s ...

      Trade tensions, OPEC+ production hikes weigh down on oil & gas credit outlook

      17/4/2025 Research

      Trade tensions, OPEC+ production hikes weigh down on oil & ...

      Scope affirms B+ issuer rating on consumer goods company Naturtex and revises Outlook to Stable

      15/4/2025 Rating announcement

      Scope affirms B+ issuer rating on consumer goods company ...

      Scope proposes an update to its Chemicals Rating Methodology and invites comments

      14/4/2025 Research

      Scope proposes an update to its Chemicals Rating Methodology ...

      US tariff increases to have uneven direct cashflow, credit impact on European corporates

      11/4/2025 Research

      US tariff increases to have uneven direct cashflow, credit ...

      Scope proposes an update to its Pharmaceutical Companies’ Rating Methodology and invites comments

      4/4/2025 Research

      Scope proposes an update to its Pharmaceutical Companies’ ...